Research Article
Interval Colorectal Cancers following Guaiac Fecal Occult Blood Testing in the Ontario ColonCancerCheck Program
Table 3
CRC diagnosed within 24 months following gFOBT by baseline and subsequent screen, gFOBT result, sex, and anatomic CRC site.
| | CRC following positive gFOBT | CRC following normal gFOBT (interval cancer) |
| Baseline gFOBT screen | CRC following baseline screen | 762/1,243 (61.30%) | 481/1,243 (38.70%) | CRC among males following baseline screen | 501/755 (66.36%) | 254/755 (33.64%) | CRC site among males | | | Distal anatomic CRC site | 331/501 (66.07%) | 164/254 (64.57%) | Another anatomic CRC site | 170/501 (33.93%) | 90/254 (35.43%) | CRC among females following baseline screen | 261/488 (53.48%) | 227/488 (46.52%) | CRC site among females | | | Distal anatomic CRC site | 137/261 (52.49%) | 107/227 (47.14%) | Another anatomic CRC site | 124/261 (47.51%) | 120/227 (52.86%) |
| Subsequent gFOBT screen | CRC following subsequent screen | 171/348 (49.14%) | 177/348 (50.86%) | CRC among males following subsequent screen | 106/195 (54.36%) | 89/195 (45.64%) | CRC site among males | | | Distal anatomic CRC site | 75/106 (70.75%) | 57/89 (64.04%) | Another anatomic CRC site | 31/106 (29.25%) | 32/89 (35.96%) | CRC among females following subsequent screen | 65/153 (42.48%) | 88/153 (57.52%) | CRC site among females | | | Distal anatomic CRC site | 38/65 (58.46%) | 51/88 (57.95%) | Another anatomic CRC site | 27/65 (41.54%) | 37/88 (42.05%) |
|
|
Row percent. Cell percent.
|